Underutilization of CRS, HIPEC & PIPAC in peritoneal mesothelioma across a German nationwide cohort

德国全国性队列研究显示,CRS、HIPEC 和 PIPAC 在腹膜间皮瘤治疗中应用不足。

阅读:3

Abstract

This retrospective cohort study utilizes a nationwide database to provide information about the epidemiology and surgical treatment practices of peritoneal mesothelioma in Germany over the years 2019 to 2024. Data collected by the German Institute for the Hospital Remuneration System (InEK) was examined by age, sex, treatment with HIPEC, PIPAC, or peritonectomy, ICU stay, type of hospital, and duration of stay. Additionally, the Patient Clinical Complexity Level (PCCL) - ranging from 0 to 6 - was analyzed. In total 3394 patients with peritoneal mesothelioma were recorded during the years 2019 to 2024 in Germany, with an average annual incidence of 0.68 per 100,000 inhabitants. The mean duration of hospital stay was 9 days. The median PCCL was 1. The median patient age group was 65 to 74. 16% of patients had an ICU stay. Most patients were treated at maximum care hospitals with over 1000 beds. Only 9% of patients received HIPEC treatment. 15% received some form of peritonectomy. PIPAC was performed on only 5% of the patients. In total, considering that patients can be coded with multiple procedures, 20% of all patients received surgical therapy. It was demonstrated that only a small percentage of patients received HIPEC, CRS, or PIPAC. This shows a grave discrepancy between guideline-recommendations and actual clinical practice. Potential reasons could be a lack of consideration of these procedures or misleading economic incentives. Ultimately, the findings highlight the need for increased awareness of peritoneal mesothelioma and underscore the importance to address the aforementioned observed discrepancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。